These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15682483)

  • 1. YMDD mutations in patients with chronic hepatitis B untreated with antiviral medicines.
    Huang ZM; Huang QW; Qin YQ; He YZ; Qin HJ; Zhou YN; Xu X; Huang MJ
    World J Gastroenterol; 2005 Feb; 11(6):867-70. PubMed ID: 15682483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and distribution of hepatitis B virus genotypes in Guangxi Zhuang population.
    Huang ZM; Huang QW; Qin YQ; Huang CH; Qin HJ; Zhou YN; Xu X; Lu CL
    World J Gastroenterol; 2005 Nov; 11(41):6525-9. PubMed ID: 16425428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YMDD motif mutations in chronic hepatitis B antiviral treatment naïve patients: a multi-center study.
    Tan YW; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    Braz J Infect Dis; 2012; 16(3):250-5. PubMed ID: 22729192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment.
    Wu F; Wu MJ; Zhuge XL; Zhu SM; Zhu B
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):172-6. PubMed ID: 22484586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between B virus hepatitis genotypes and therapeutic efficacy in early treatment for chronic hepatitis B by using lamivudine].
    Song SJ; Zhuang H; Yan J; Wei HS; He ZP; Song C; Dong QM; Xiao YP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2005 May; 39(3):203-5. PubMed ID: 15938857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The naturally occurring YMDD mutation among patients chronically infected HBV and untreated with lamivudine: a systematic review and meta-analysis.
    Tan Y; Ding K; Su J; Trinh X; Peng Z; Gong Y; Chen L; Cui Q; Lei N; Chen X; Yu R
    PLoS One; 2012; 7(3):e32789. PubMed ID: 22479339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment.
    Kirishima T; Okanoue T; Daimon Y; Itoh Y; Nakamura H; Morita A; Toyama T; Minami M
    J Hepatol; 2002 Aug; 37(2):259-65. PubMed ID: 12127432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
    Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
    J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
    Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
    Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
    Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
    Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of pre-core mutant chronic hepatitis B.
    Papatheodoridis GV; Hadziyannis SJ
    J Viral Hepat; 2001 Sep; 8(5):311-21. PubMed ID: 11555188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.